APOB and neoplasm: Specifically, a non-oncogenetic mutation of apolipoprotein B is observed, which can result in apolipoprotein B inactivation and is associated with the overexpression of oncogenic regulators and the downregulation of tumour suppressors, resulting in poorer survival outcomes.